2017-10-17 Editorial Advisory Group Face-to-face meeting, Bratislava

Zoom Meeting Details

SNOMED Int'l Editorial Advisory group

SNOMED International - Editorial advisory group conference call UTC

Please join my meeting from your computer, tablet or smartphone.

https://snomed.zoom.us/j/680315399

Date 20171017 0700-1500 UTC

0900-1700 Bratislava time

0500-1300 Eastern Daylight Time

Attendees

Chair:

Jim Case

AG Members

- Keith Campbell
- Guillermo Reynoso
- Bruce Goldberg
- Paul Amos
- Jeremy Rogers

Observers:

- Monica Harry
- Krista Lilly
- Maria Braithwaite
- Donna Morgan
- Maggie Lau
- Ismat Mohd Sulaiman
- Toni Morrison
- Eric Rose
- Cathy Richardson
- Elze de Groot
- Katrien Scheerlinck
- Nicola Ingram
- Regis Charlot
- Phuong Skovgaard
- Gary DickinsonTimothy Williams
- Emma Melhuish
- Alejandro Lopez Osornio
- Matt Cordell
- Penni Hernandez
- Candy Barth
- Rita BarsoumCorey Smith
- Scott Campbell
- Mary Kennedy
- Raj Dash
- James R. Campbell

Apologies

Jeff Pierson

Meeting Files

Sepsis models.pptx

Complications and sequelae update.pptx

Allergy Topics.pptx

2017 KDIGO Update

Meeting recording

The folder containing the meeting recordings is located here.



Objectives

• Obtain consensus on agenda items

Discussion items

| | Description | Owner | Notes | Disc |
|---|--|---|--|-----------------------|
| | Call to order and role call | JCA | | |
| | Conflicts of interest | JCA | | |
| | Approval of minutes 20170928 | | | |
| 3 | Continued from 20170928: Change of | JCA | Based on requests from UKTC: The concepts are | Sumr past discu |
| | name for | | 726018006[Autosomal dominant medullary cystic kidney disease (disorder)] | |
| | genetic diseases | | 723373006[Autosomal dominant medullary cystic kidney disease with hyperuricemia (disorder)] | |
| | | | 726017001 Autosomal dominant medullary cystic kidney disease without hyperuricemia (disorder) | |
| | | | The FON feethers assessed a first with Orange of One hand One size these Defenders. The assessed feet the UKTO is | |
| | | | The FSN for these concepts align with Orphanet, OMIM and Genetics Home Reference. The request from the UKTC is | |
| | | | 1 TO | |
| | | | All terms should ideally be replaced by autosomal dominant tubulointerstitial kidney disease (ADTKD) (see KDIGO report). The above terms are not | |
| | | | necessarily the same and don't really reflect the improved clinical descriptions of the disease based on genetics. ADTKD reflects the inheritance, common phenotype caused by different mutations and can be used for suspected cases. This is well described in the KDIGO report. They also make the point it is | |
| | | | prientitype caused by dimeterial mutations and can be used to suspected cases. This is well described in the KDIGO report. They also make the point it is a simple term to use and that MCKD is frankly inaccurate! | |
| | | | a simple term to use and that word is namely maccurate: | |
| | | | A the standard from the standard from MOVD 4 and 0 and the standard from the standar | |
| | | | As above. I would favour not using these terms MCKD 1 and 2 even though they may be commonly used at present. ADTKD-UMOD or ADTKD-MUC1 | |
| | | | would be the preferred names. The list of genes is also increasing making a single term more appropriate. | |
| | | | | |
| | | · · | ADTKD would be the parent and the children would be ADTKD associated with UMOD mutations and ADTKD associated with MUC1 mutations. | |
| | | | | |
| | | It is anticipated that this type of request will become more frequent as the move towards genomics continues. | It is anticipated that this type of request will become more frequent as the move towards genomics continues. | |
| | | | | |
| | | | Question: Do we go with the current naming convention to align with Orphanet (our current "Source of truth") or try to keep pace with the evolving nature | |
| | | | of content in this area? | |
| | | | | |
| | | | 10/6/2017: Response from Orphanet | |
| | | | 16.6.25 Through the First Copyright | |
| | | | After checking, I confirm the proposed modification of nomenclature from your contact. These modifications don't change the concepts nor the current | |
| | | | mappings. | |
| | | | To sum up, here is the new configuration: | |
| | | | To sain up, note to the form guidator. | |
| | | | ORPHA34149 Autosomal dominant tubulointerstitial kidney disease (Disease) | |
| | | | ORPHA88949 MUC1-related autosomal dominant tubulointerstitial kidney disease (Clinical subtype) (formerly MCKD1) | |
| | | | ORPHA88950 UMOD-related autosomal dominant tubulointerstitial kidney disease (clinical subtype) (formerly MCKD2) | |
| | | | ORPHA217330 REN-related autosomal dominant tubulointerstitial kidney disease (Clinical subtype) (formerly FJHN type 2) | |
| | | | on the first section and the section of the section | |
| | | | Question: Do we change the FSN or inactivate and replace? In this case it is clear from the response that the "meaning" of the concept is unchanged. For | |
| | | | westion. On we clearly a lier F3N of inactivate and replace; in this case it is clear from the response that use in remaining on the concept is unchanged. For organisms, we have adopted the policy that when taxonomic names change, it is not the organism that changes, but the term representing the organism. | |
| | | | thus we rename the FSN for the concept and retain the "older" term as a historical synonym as the naming transition for searching convenience. Should | |
| | | | we adout the same policy for disorders, or does this constitute a substantive change compelling us to inactivate and replace? | |
| | | | we dust the same policy for disorders, or does this constitute a substantive charge compening as to macritate and replace : | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | 1 |

Orphane release c (from Ma Braithwa

Orphanet an ongoir cycle of rifor new definitions changes i website, t do not cu routinely i me of a c to the nar a particulientry but ask them possible t provide the informatic

We agree they will p me with a changes I additions, deprecate obsolete entries) the per year I and Octol allow me make correlates. will preve problems had previ where a r concept the been pub almost simultane with Orph deprecatit their entry

10/17/201 Discussi

| | | | Suggeste we need I specific w guidance what con: "change I meaning" that time, safest third do is to re and repla Also sugg that the o term be retained a descriptic associate the new concept. |
|---|---|-----|--|
| | | | The example the policy for organiname character was pressibut this is primitive hierarchy cases discussed there is not change to underlying modeling, a name company to the policy for the |
| | | | Terms the inherently vague or ambiguou are clarifin name che or addition relationsh would ma inactivatic replacem Additiona |
| | | | documen http://ped aappublic org/conte /2016/04/ /peds.201 0590 |
| | | | Do we ne new inact status the reflects th inactivatic to a chan understar of the cor i.e. refine knowledg |
| 4 | Demo: Batch structural changes to existing content | GRE | Brief demonstr of the too that will b to revisec inconsiste identified structure SNOMEE content. Examples types of patterns t will be addresse be found ://qa.snor org/ |

| 5 | ECE Update | BGO | Sepsis/Sepsis-associated organ dysfunction. The third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) published in 2016 state sepsis is a multi organ dysfunction syndrome due to an infection or more specifically due to an dysregulated host response to infection. Current model places sepsis as a subtype of SIRS and infectious disease which is not consistent with Sepsis-3 definition. Proposed model: IsA Multiple organ dysfunction syndrome due to infection. | BGO p the dis form th meetin previou See sli |
|---|---|-----|---|--|
| | | | and innections disease which is not consistent with Sepsis-3 definition. Proposed model, is a within organity statistical syndrome due to finection. Discussion by ECE | Sepsis pptx a |
| | | | Sepsis models.pptx Question: Would a new pathological process of dysregulated host response be required in order to fully define sepsis? | Is the meaning the currepression SNI going issues if we consider the current words wrong |
| | | | | Discuss to the the ne pathol process in value definith Suggesthere in for an Information and Information immures pool in the suggestion of |
| | | | | GRE E up the the inconsuse of PATH PROC This le severe restric range. Discus expan range the ed guidar be tigh ensure consis |
| | | | | Group that Se should remod accord new do GRE n with the introduction of the sufficience of the training sufficienc |
| 6 | Findings related to skin wounds | JCA | A number of requests related to findings related to surgical skin wounds and pressure injury findings reveal an issue with current structure. Most of the requested terms are Findings related to skin wounds, but currently 262526004 [Wound of skin (disorder)] is a disorder, so cannot be used as a parent for findings related to skin wounds. There is currently 225552003 [Wound finding), but it is not specific to skin. 262526004 [Wound of skin (disorder) [currently has 65 immediate subtypes, many of which could reasonably be viewed as findings (e.g. "Abrasion of X"). Need to make a determination of whether observations related to wounds (i.e. color, discharge, odor) should be placed in a subhierarchy different from the "Wound (disorder)" itself. | Agree- wound disord and fir about should classif wound |
| 7 | Specimen from subjects other than the patient | JCA | Currently we have many concepts in the specimen hierarchy that include "from patient" as well as those that do not include it as an ancestor. Since the subject of record is the default for specimens, we would like to retire these apparent duplicates, but then we run into the problem of specimens derived from other sources such as donors or normal control patients. | |

The "soft default of specimen originating the patier where the problem I Currently, organizat the value: SPECIME SOURCE causes st specimen patients to classify u the group term "Spe from patie

Suggestic make a m general te "Patient fi specimen donor", bi would onl address t the SPEC SOURCE


KCA men the many issues wil "soft defa For the m part, thes specimen used as c from the patient. However, the FSN t need to b changed reflect that these are the patient Does the need to re explicitly! comes fro patient?

Should ex Specimer the SPEC SOURCE explicitly defined? this conte comes frc where the concept it within the record. This history of terms ma provide so the reason as to why terms well created. Fexample, restriction where conculd be in earlier versions c v2 (i.e. pr v2.5) mes there was place to padditional informatic around the specimen suggeste a module that they eventually segregate a module that they eventually segregate away fron core.

| | | Non-patie |
|--|--|---------------------------|
| | | oriented |
| | | specimen |
| | | the major |
| | | now and |
| | | of the use |
| | | cases stil |
| | | the older |
| | | transport |
| | | structure, |
| | | meaning |
| | | need pre- coordinat |
| | | content. |
| | | content. |
| | | What are |
| | | requireme |
| | | for the ad |
| | | of these t |
| | | and what |
| | | major fun |
| | | of the cor |
| | | address t |
| | | requireme |
| | | More mod |
| | | transport mechanis |
| | | such as F |
| | | do not ne |
| | | level of pi |
| | | coordinat |
| | | |
| | | Comment |
| | | IMO indic |
| | | that most |
| | | of the |
| | | terminolo |
| | | not suffici sophistica |
| | | use eithe |
| | | terminolo |
| | | model ba |
| | | post- |
| | | coordinat |
| | | |
| | | The long- |
| | | standing |
| | | practice c |
| | | using unspecifie |
| | | Specimer |
| | | provides |
| | | substantia |
| | | challenge |
| | | revising tl |
| | | make it e: |
| | | as it woul |
| | | result in a |
| | | number o changes |
| | | may impa |
| | | implemer |
| | | F |
| | | |

| | 1 | 1 | | |
|---|-----------------------|-----|---|---------------------------|
| 8 | WAS-A Inactivation | JCA | Concerns have been expressed about the impending inactivation of existing WAS-A relationships: | Jeremy R presented |
| | redux | | "This topic has consulted with the CMAG and UKTC. The feedback from CMAG was that this should not be a priority. The size and efforts are small for | use case |
| | | | content maintenance. The potential impact could be high if we make changes. The feedback from UKTC was to delay the changes until 2018 when they | these terr |
| | | | move to RF2. Furthermore, they still think it would be useful to provide information for WAS A by technical means centrally." | within the UKTC. |
| | | | See additional discussion | |
| | | | | Guillermo Reynoso |
| | | | | Described |
| | | | | history of |
| | | | | A relation The obse |
| | | | | was made |
| | | | | these |
| | | | | relationsh have not |
| | | | | updated f |
| | | | | number o years so |
| | | | | represent |
| | | | | full scope |
| | | | | inactivationsh |
| | | | | The WAS |
| | | | | relationsh no longer |
| | | | | available |
| | | | | was prima |
| | | | | used to m "limited" |
| | | | | concepts, |
| | | | | were mac inactive ir |
| | | | | indonve ii |
| | | | | The ability |
| | | | | segregate from the c |
| | | | | using a m |
| | | | | approach also sugg |
| | | | | Also sugg |
| | | | | that these moved ba |
| | | | | the UK |
| | | | | extension that they |
| | | | | full contro |
| | | | | how to us |
| | | | | them as t are not ne |
| | | | | by other |
| | | | | extension |
| | | | | It was |
| | | | | suggester if there is |
| | | | | need to h |
| | | | | access to A relation |
| | | | | for transit |
| | | | | closure, tl |
| | | | | complete these car |
| | | | | reconstru |
| | | | | from the I files, whic |
| | | | | would be |
| | | | | complete |
| | | | | the currer |
| | | | | There wa |
| | | | | discussio about the |
| | | | | ambiguity |
| | | | | REPLACI |
| | | | | BY, which also no lo |
| | | | | used. |
| | | | | |
| | | | I . | |

v



| ı | ı | ı | 1 |
|----|--|-----|---|
| | | | The asso problem i need for a definition what is m by "infect device". It view the presence device as another acquired structure, these may be complicat The timin the infecti relation to procedure be the rea to classify somethin Complica a procedule, within a certain nu of days). |
| | | | The two approach "close to reality", w multi-dimension and chall to determ "simplified model" the describes is certain, determine whether somethin, complicat not is ofte unknown, testing wire to be don see the in of applyin simplified model. If not meet needs fro classificar standpoin a more comodel will needed. |
| | | | This argu the use of ASSOCIA WITH as relationsh devices. |
| | | | For the procedure such as "Removal prosthesis to infectio possibility use of HA FOCUS. |
| | | | There are guideline: the evalus of patient to implant where pre existing infection is cause abi of the procedure |
| | | | Clarificati the currer understar of Complica can be fo re. |
| 11 | "Acquired" disorders vs. Congenital disorders | JCA | There are "Acquired disorders SNOMEC The vast majority a primitive. |

~

v

• There are existing "Acquired X (morphologic abnormality)" concepts, but these are very much analogous to the "Congenital X" morphologies that

There are existing "Acquired X (morphologic abnormality)" concepts, but these are very much analogous to the "Congenital X" morphologies that we are trying hard to get rid of.

"Acquired" and "Congenital" are not morphologies, but timeframes. We do not have a way of denoting "All periods of life after birth" like we do for "Congenital". If we did, then we could create a fully defined concept grouper of "Acquired disorder", which would subsume all concepts that had any OCCURRENCE value later than "At birth", but then it would require that all acquired disorders have a valid OCCURRENCE relationship. This approach might also open the door that all disorders that are not specifically "Congenital" have an OCCURRENCE relationship stating that it is required, which seems to be "overmodeling". While we can use the "Acquired deformity" morphology concepts currently, due to the lack of many useful subtypes of "Acquired X" morphologies, it would only be a partial solution.

The HoT is not in favor of recreating the problem in "Acquired" concepts that would mimic the type of concepts we are trying to inactivate in the Congenital space. However, the current guidance related to "Congenital" is not totally correct, because there are many conditions that can ONLY be congenital, even if the FSN does not state it (For example, aplasias or supernumerary structures). So the guidance does need to be updated.

One potential solution is to create a primitive grouper of "Acquired disorder" and then using that as the proximal primitive parent, adding the necessary relationships to make acquired disorders defined. It is a kludge, but it would allow for full definition.

There are alternative discuss:

~

Cr

annt instruction and the control of the control of

This This demonstr need to s disjointne which will hopefully supported the conce model in the near futur There are challenge using per life as a v classify the What is the case to me the distinct between congenita acquired. the exam "anodonti

There is a the distinute the them hereditary "congenit which are conflated disease naming. Hereditary disease of the them hereditary diseases." diseases manifest l life. Would these be considere "acquired What do mean who say "acqu

| | | | | Could lim use of the period of grouper fithose disiwhere the specifies "acquired Would disthat maniflater in life are actua genetic be incorrectly classified acquired disorder (were creat Would the an advan having thi |
|----|---------------------------|-----|---|---|
| | | | | level grou The challi is how to represent acquisitio the trait a opposed clinical manifesta the trait. Suggeste a new qu: value of "natal" be created to aggregate periods or that would used to d "Acquired" |
| | | | | condition: 2017-11-I related tra exists: P(The work related to item will t linked to 1 tracker. |
| 12 | Update of EAG Workplan | JCA | Review and revision of current workplan | Continuer next call (lack of tin |

| 13 | Use of the Oxford comma in FSNs | JCA | The Oxford comma is a comma added after the penultimate term in a list, e.g. For example "Disorder of head, neck, and shoulders". The purpose if its use is to make explicit the fact that the terms are part of a list. The editorial guide is silent about its use, but the example provided does not use the Oxford comma. There are currently 347 FSNs in SNOMED CT that use the Oxford comma. Most of these are terms obtained from other terminology, such as ICD and nursing. There are 2500 FSNs that contain comma delimited lists, but do not use the Oxford comma. Question: Should SNOMED CT be consistent in the use of this grammar mark or maintain fidelity to the original source of the terms that do use it? | KCA expr support fo Oxford cc The ques being whi there sho a retroact applicatio FSNs. It c results in the short would not could not could not could not requireme inactivatic replacem JRO was favor of u the Oxfor comma w does not value. The challenge provide e guidance what the condition that requirements in the comma w does not value. The |
|----|---------------------------------------|-----|--|--|
| | | | | 230 01 110 |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| 14 | AoB | Group | Placement of "conditions" and "predispositions" as clinical findings as opposed to disorders BGO | Bruce Go presented |
|----|-----|-------|--|----------------------------|
| | | | Device disorder vs. device failure | issues fro |
| | | | | ECE mee |
| | | | | that requi additional |
| | | | | |
| | | | | Complica |
| | | | | and sequ update.pr |
| | | | | |
| | | | | Device |
| | | | | complica |
| | | | | Problems |
| | | | | the device should be |
| | | | | finding ar |
| | | | | a disorde would alk |
| | | | | some |
| | | | | rearrange of the cur |
| | | | | device pri |
| | | | | findings. modleing |
| | | | | structure |
| | | | | be to use INTERPR |
| | | | | /HAS |
| | | | | INTERPR ON pair to |
| | | | | ON pair to define the |
| | | | | findings. |
| | | | | Should al |
| | | | | create a r |
| | | | | specific "c failure" to |
| | | | | segregate |
| | | | | general e equipmer |
| | | | | failure. |
| | | | | desire to |
| | | | | more exa |
| | | | | for each c three patt |
| | | | | unee pau |
| | | | | Hypersei |
| | | | | y conditi remodeli |
| | | | | finding: |
| | | | | A 11 7 |
| | | | | Allergy T pptx |
| | | | | |
| | | | | Predispos are not |
| | | | | disorders |
| | | | | as they de have a |
| | | | | pathologi |
| | | | | process. Proposed |
| | | | | move a la |
| | | | | number o concepts |
| | | | | under dis |
| | | | | to finding: |
| | | | | Because |
| | | | | proposal |
| | | | | simply ch the sema |
| | | | | tag within |
| | | | | same hie would not |
| | | | | require |
| | | | | inactivation recreation |
| | | | | these cor |
| | | | | The distin |
| | | | | between |
| | | | | findings a diseases |
| | | | | brought u |
| | | | | problems associate |
| | | | | this distin |
| | | | | and the duplicatio |
| | | | | terms as |
| | | | | findings a disorders |
| | | | | discussed |
| | | | | asked to: |
| | | | | list of thes duplicates |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

v

~

| 15 | Future meetings | JCA | Next |
|----|-----------------|-----|------------------|
| | | | conferenc TBD |